Study With Lu AF11167 for the Treatment of Negative Symptoms in Patients With Schizophrenia

NCT03793712 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

168

Enrollment

INDUSTRY

Sponsor class

Stopped Lack of efficacy based on interim analysis

Conditions

Schizophrenia

Interventions

DRUG: Lu AF11167 (1-2 mg/day)
DRUG: Lu AF11167 (3-4 mg/day)
DRUG: Placebo

Sponsor

H. Lundbeck A/S